Article Dans Une Revue European Journal of Nuclear Medicine and Molecular Imaging Année : 2019

Radiotherapy boost in patients with hypoxic lesions identified by 18F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up].

Résumé

Chemoradiotherapy is the reference curative-intent treatment for nonresectable locally advanced non-small-cell lung carcinoma (NSCLC), with unsatisfactory survival, partially due to radiation resistance in hypoxic tissues. The objective was to update survival and toxicity at 3 years following radiotherapy boost to hypoxic tumours in NSCLC patients treated with curative-intent chemoradiotherapy.

Fichier non déposé

Dates et versions

hal-02087912 , version 1 (02-04-2019)

Identifiants

Citer

Pierre Vera, Sorina-Dana Mihailescu, Justine Lequesne, Romain Modzelewski, Pierre Bohn, et al.. Radiotherapy boost in patients with hypoxic lesions identified by 18F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up].. European Journal of Nuclear Medicine and Molecular Imaging, 2019, ⟨10.1007/s00259-019-04285-9⟩. ⟨hal-02087912⟩
126 Consultations
0 Téléchargements

Altmetric

Partager

  • More